Delisting risk
Jasper Therapeutics
Develops complement inhibitors and targeted antibodies for immunological disorders.
$0.7140
After-hours close+0.02 (+3.02%)
At close$0.6931(−0.87%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 97.30%Insiders 5.01%
Institutions and insiders are filed separately and overlap, so together they can pass the whole company. No split is drawn from them.
Shares outstanding 16.25M · Float 13.78M · 84.8% free float
Institutions13F, as of Mar 31, 2026
60 holders · 15.81M shares · 13 new positions · 28 increased · 13 reduced · 9 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Velan Capital Investment Management LP | 2.67M | 16.42% | 0 | May 15, 2026 |
| Millennium Management LLC | 1.62M | 9.95% | +543.7K | May 15, 2026 |
| Acorn Capital Advisors, LLC | 1.41M | 8.68% | −375.0K | May 15, 2026 |
| Kingdon Capital Management, L.L.C. | 1.35M | 8.32% | +1.35M | May 15, 2026 |
| Morgan Stanley | 1.33M | 8.20% | −636.4K | May 15, 2026 |
| Vanguard Capital Management LLC | 1.17M | 7.21% | +1.17Mnew | May 15, 2026 |
| Rock Springs Capital Management LP | 1.10M | 6.77% | 0 | May 15, 2026 |
| Carlyle Group Inc. | 1.07M | 6.56% | 0 | May 8, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Velan Capital Investment Management LPincl. Kapoor Vishal, Velan Capital Master Fund LP +9 more | 9.88% | 3.35M | 13D | Jul 20, 2026 ↗ |
| Velan Capital Master Fund LP | 8.90% | 3.04M | 13G | Aug 17, 2026 ↗ |
| T. Rowe Price Investment Management, Inc. | 7.10% | 2.06M | 13G | Nov 14, 2025 ↗ |
| Integrated Core Strategies (US) LLC | 5.80% | 1.62M | 13G | Feb 25, 2026 ↗ |
| BlackRock, Inc. | 5.30% | 800.0K | Oct 22, 2024 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Patrick J. Crutcher | director | 518.3K | 3.19% | Jul 20, 2026 |
| Judith Anne Shizuru | director | 156.9K | 0.97% | Sep 24, 2025 |
| Ron Martell | director, officer: President and CEO | 74.1K | 0.46% | Sep 24, 2025 |
| Thomas G. Wiggans | director | 41.0K | 0.25% | Sep 24, 2025 |
| Svetlana Lucas | director | 20.0K | 0.12% | Sep 24, 2025 |
| Wenru Song | officer: EVP, Head of R&D | 3.2K | 0.02% | Jul 22, 2026 |
9 ten-percent owners hold 4.68M shares by Form 4, outside the officers-and-directors figure above · 9 people have not refiled in the last 18 months (500.3K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 20, 2026 | Matthew E. Rosofficer: Chief Operating Officer | Purchase | 881 | 881 | |
| Jul 20, 2026 | Patrick J. Crutcherdirector | Purchase | 888 | 888 | |
| Sep 22, 2025 | Judith Anne Shizurudirector | Purchase · 2 lots | 82,000 | $2.68 | 197,901 |
| Sep 22, 2025 | Ron Martelldirector, officer: President and CEO | Purchase · 2 lots | 82,000 | $2.68 | 115,118 |
| Sep 22, 2025 | Svetlana Lucasdirector | Purchase · 2 lots | 40,000 | $2.68 | 40,000 |
| Sep 22, 2025 | Thomas G. Wiggansdirector | Purchase · 2 lots | 82,000 | $2.68 | 82,000 |
CongressHouse and Senate disclosures
Not reported.